PhaseBio Pharmaceuticals Inc (PHAS) stock is down -61.44% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives PHAS stock a score of 34 out of a possible 100.
That rank is chiefly influenced by a short-term technical score of 13. PHAS's rank also includes a long-term technical score of 18. The fundamental score for PHAS is 70. In addition to the average rating from Wall Street analysts, PHAS stock has a mean target price of $16.00. This means analysts expect the stock to climb 1200.81% over the next 12 months. PHAS has an Overall Score of 34. Find out what this means to you and get the rest of the rankings on PHAS!